BACKGROUND: Neonatal herpes simplex virus (HSV) disease results in unacceptable morbidity and mortality. The primary humoral immune response to natural infection is neutralizing antibodies (Abs). However, Abs that activate Fc gama receptors (FcγRs) and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) may play a dominant role in protection. In adult mice, a single-cycle HSV candidate vaccine deleted in glycoprotein-D (ΔgD-2) that induces ADCC provided complete protection against HSV disease and prevented the establishment of latency. Passive transfer studies showed that Abs were sufficient for protection. The current study tested the hypothesis that maternal immunization with ΔgD-2 would protect neonates. METHODS: C57BL/6 female mice were vaccinated 3 weeks apart with ΔgD-2, and pups were challenged at different times postnatally with lethal doses of HSV-1 or HSV-2. Concentration and functionality of Abs and immune cells were assessed. RESULTS: Maternal ΔgD-2 immunization provided significant protection and reduced viral dissemination after lethal challenge with HSV-1 or HSV-2. Protection correlated with Abs acquired transplacentally or from breastmilk that mediated ADCC. Protection was reduced when pups were challenged on Day 1 of life, and this was associated with decreased ability of newborn cells to mediate Ab-dependent cell killing. CONCLUSIONS: Antibodies mediating ADCC provide significant protection against neonatal HSV.
BACKGROUND: Neonatal herpes simplex virus (HSV) disease results in unacceptable morbidity and mortality. The primary humoral immune response to natural infection is neutralizing antibodies (Abs). However, Abs that activate Fc gama receptors (FcγRs) and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) may play a dominant role in protection. In adult mice, a single-cycle HSV candidate vaccine deleted in glycoprotein-D (ΔgD-2) that induces ADCC provided complete protection against HSV disease and prevented the establishment of latency. Passive transfer studies showed that Abs were sufficient for protection. The current study tested the hypothesis that maternal immunization with ΔgD-2 would protect neonates. METHODS: C57BL/6 female mice were vaccinated 3 weeks apart with ΔgD-2, and pups were challenged at different times postnatally with lethal doses of HSV-1 or HSV-2. Concentration and functionality of Abs and immune cells were assessed. RESULTS: Maternal ΔgD-2 immunization provided significant protection and reduced viral dissemination after lethal challenge with HSV-1 or HSV-2. Protection correlated with Abs acquired transplacentally or from breastmilk that mediated ADCC. Protection was reduced when pups were challenged on Day 1 of life, and this was associated with decreased ability of newborn cells to mediate Ab-dependent cell killing. CONCLUSIONS: Antibodies mediating ADCC provide significant protection against neonatal HSV.
Authors: Chaya D Patel; Iara M Backes; Sean A Taylor; Yike Jiang; Arnaud Marchant; Jean M Pesola; Donald M Coen; David M Knipe; Margaret E Ackerman; David A Leib Journal: Sci Transl Med Date: 2019-04-10 Impact factor: 17.956
Authors: Z A Brown; S Selke; J Zeh; J Kopelman; A Maslow; R L Ashley; D H Watts; S Berry; M Herd; L Corey Journal: N Engl J Med Date: 1997-08-21 Impact factor: 91.245
Authors: Geert Leroux-Roels; Frédéric Clément; Pierre Vandepapelière; Marc Fourneau; Thomas C Heineman; Gary Dubin Journal: Hum Vaccin Immunother Date: 2013-02-22 Impact factor: 3.452
Authors: Christopher Petro; Pablo A González; Natalia Cheshenko; Thomas Jandl; Nazanin Khajoueinejad; Angèle Bénard; Mayami Sengupta; Betsy C Herold; William R Jacobs Journal: Elife Date: 2015-03-10 Impact factor: 8.140
Authors: Jonathon E Himes; Ria Goswami; Riley J Mangan; Amit Kumar; Thomas L Jeffries; Joshua A Eudailey; Holly Heimsath; Quang N Nguyen; Justin Pollara; Celia LaBranche; Meng Chen; Nathan A Vandergrift; James W Peacock; Faith Schiro; Cecily Midkiff; Guido Ferrari; David C Montefiori; Xavier Alvarez Hernandez; Pyone Pyone Aye; Sallie R Permar Journal: Mucosal Immunol Date: 2018-08-16 Impact factor: 8.701
Authors: Katharine J Looker; Amalia S Magaret; Margaret T May; Katherine M E Turner; Peter Vickerman; Lori M Newman; Sami L Gottlieb Journal: Lancet Glob Health Date: 2017-01-31 Impact factor: 26.763
Authors: Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib Journal: J Virol Date: 2020-05-18 Impact factor: 5.103
Authors: Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman Journal: Transl Res Date: 2020-03-16 Impact factor: 7.012
Authors: Iara M Backes; Brook K Byrd; Matthew D Slein; Chaya D Patel; Sean A Taylor; Callaghan R Garland; Scott W MacDonald; Alejandro B Balazs; Scott C Davis; Margaret E Ackerman; David A Leib Journal: J Exp Med Date: 2022-09-26 Impact factor: 17.579
Authors: Natalie L M Ramsey; Maria Visciano; Richard Hunte; Lip Nam Loh; Clare Burn Aschner; William R Jacobs; Betsy C Herold Journal: J Virol Date: 2020-06-16 Impact factor: 5.103
Authors: Tulika Singh; Claire E Otero; Katherine Li; Sarah M Valencia; Ashley N Nelson; Sallie R Permar Journal: Front Pediatr Date: 2020-12-15 Impact factor: 3.418
Authors: Clare Burn Aschner; Lip Nam Loh; Benjamin Galen; Isabel Delwel; Rohit K Jangra; Scott J Garforth; Kartik Chandran; Steven Almo; William R Jacobs; Carl F Ware; Betsy C Herold Journal: Sci Immunol Date: 2020-08-14
Authors: Philip C LaTourette; Sita Awasthi; Angela Desmond; Norbert Pardi; Gary H Cohen; Drew Weissman; Harvey M Friedman Journal: Vaccine Date: 2020-10-09 Impact factor: 3.641